17:28 , Jan 17, 2019 |  BC Week In Review  |  Company News

NICE recommends against Aimovig from Novartis

The U.K.’s NICE issued draft guidance not recommending Aimovig erenumab from Novartis AG (NYSE:NVS; SIX:NOVN) to prevent chronic and episodic migraine. While the committee concluded that the evidence shows that Aimovig is effective, it said...
19:20 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Biohaven nets $125M ahead of NDA submissions

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHNV) raised $125 million Dec. 12 through the sale of 3.3 million shares at $37.25 in an upsized follow-on. Following positive Phase III data reported this month for rimegepant for...
18:37 , Dec 13, 2018 |  BC Extra  |  Financial News

Biohaven nets $125M ahead of NDA submissions

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHNV) raised $125 million late Wednesday through the sale of 3.3 million shares at $37.25 in an upsized follow-on. Following positive Phase III data reported this month for rimegepant for...
17:58 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) said its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for the acute treatment of migraine. The company updated its...
20:13 , Dec 3, 2018 |  BC Extra  |  Clinical News

Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) added $8.66 (25%) to $42.65 on Monday after reporting that its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for...
18:02 , Oct 19, 2018 |  BC Week In Review  |  Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Oct. 17. The PBM gave the nod to Aimovig erenumab-aooe from...
23:44 , Oct 18, 2018 |  BC Innovations  |  Targets & Mechanisms

Volkow: why pain and addiction will go personalized

While addiction still carries a social stigma, neuroscience research not only supports the view that it is a disease, but is starting to paint a more nuanced picture of the variety of mechanistic pathways involved....
23:16 , Oct 17, 2018 |  BC Extra  |  Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Wednesday. The PBM gave the nod to Aimovig erenumab-aooe from Amgen...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
20:17 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves Lilly's mAb to prevent migraine

Eli Lilly and Co. (NYSE:LLY) said FDA approved Emgality galcanezumab-gnlm to prevent migraine in adults. The mAb against calcitonin-related gene peptide (CGRP) is the third in its class that FDA has approved. Lilly said Emgality...